U

University of Tennessee Health Science Center | Preventive Medicine

Research site
(Unclaimed)
Location
66 N. Pauline Street, Suite 647, Memphis, Tennessee, United States of America
Site insights

Top conditions

Carcinoma (10 trials)

Breast Cancer (7 trials)

Huntington Disease (4 trials)

Wounds and Injuries (4 trials)

Opioid-Related Disorders (4 trials)

Top treatments

Bevacizumab
Paclitaxel
Doxorubicin Hydrochloride
Ropeginterferon
Cyclophosphamide
Sorafenib Tosylate
Anastrozole
Bosentan
Tamoxifen Citrate
Lyrica

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

9 of 93
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Enrolling
Essential Thrombocythemia
Drug: Ropeginterferon alfa-2b-njft (P1101)

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Enrolling
Polycythemia Vera
Drug: Ropeginterferon alfa-2b-njft (P1101)
Drug: P1101 (Ropeginterferon alfa-2b-njft)

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known...

Enrolling
Chronic Kidney Disease
Type 2 Diabetes Mellitus
Drug: Finerenone (BAY94-8862 ) 20 mg
Drug: Empagliflozin Placebo

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...

Active, not recruiting
Metastatic Uveal Melanoma
Metastatic Ocular Melanoma
Combination Product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patie...

Active, not recruiting
Hormone-resistant Prostate Cancer
Stage IV Prostate Cancer
Drug: prednisone
Drug: enzalutamide

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profi...

Active, not recruiting
Hemophilia B
Biological: Factor IX (FIX)
Genetic: AAV5-hFIXco-Padua

IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the preven...

Active, not recruiting
Necrotizing Enterocolitis
Drug: Placebo
Drug: IBP-9414

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting
Colorectal Neoplasms
Drug: eflornithine & sulindac placebo
Drug: Eflornithine placebo & sulindac placebo

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenan...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab/rHuPH20

Trial sponsors

National Cancer Institute (NCI) logo

National Cancer Institute (NCI) (15 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems